Raze Therapeutics attracts $24 mln Series A

Raze Therapeutics has raised $24 million in Series A financing. The investors include Atlas Venture, MPM Capital Management, MS Ventures, Partners Innovation Fund, Astellas Venture Management and Novartis. In addition to the funding, Jason Rhodes, an Atlas partner, has joined the board and is serving as acting CEO. Based in Cambridge, Mass., Raze Therapeutics is a biotech firm focused on developing new cancer drugs.

North AmericaUSBriefs